Klotho Peptide: The Anti-Aging Factor That Declines With Age

Klotho is a protein first discovered in 1997 by Dr. Makoto Kuro-o at the University of Texas Southwestern Medical Center. It is named after Clotho — the Greek goddess who spins the thread of life — because of its striking link to aging and lifespan.

Mice engineered to lack Klotho age rapidly. They develop hardened arteries, bone loss, skin thinning, and organ failure — dying within weeks. Mice engineered to overproduce Klotho live 20-30% longer than normal.

In humans, Klotho exists in two main forms:

• Membrane Klotho: Anchored to cell surfaces, mainly in the kidneys and brain. It acts as a co-receptor for fibroblast growth factor 23 (FGF23), which regulates phosphate and vitamin D levels
• Soluble Klotho (s-Klotho): Released into the bloodstream after cleavage from cell membranes. This circulating form acts as a hormone, influencing tissues throughout the body

Klotho levels peak in early adulthood and decline steadily with age. By age 70, circulating s-Klotho levels are roughly half what they were at age 20. This decline parallels the onset of age-related disease. For peptide biology fundamentals, see the comprehensive peptide guide.

One of the most exciting areas of Klotho research is its effect on the brain. Higher Klotho levels consistently correlate with better cognitive performance — regardless of age.

A landmark study published in Cell Reports (2023) by Dr. Dena Dubal at UC San Francisco found that a single injection of Klotho protein improved cognitive function in aged mice within hours. The effect lasted for weeks. The mice performed significantly better on spatial memory and learning tasks.

In humans, large epidemiological studies show that people with higher circulating Klotho levels score better on cognitive tests. A study in JAMA Neurology found that higher s-Klotho was associated with larger brain volume in the prefrontal cortex and hippocampus — regions critical for decision-making and memory.

The mechanism appears to involve NMDA receptor signaling. Klotho enhances GluN2B-containing NMDA receptors in the hippocampus, strengthening long-term potentiation (LTP) — the cellular process that forms memories. It also increases BDNF (brain-derived neurotrophic factor) expression, promoting neuron survival and new connections.

For related cognitive peptide research, see the brain function peptide guide.

Low Klotho levels are a risk factor for cardiovascular and metabolic disease. Research published in Nature (2025) analyzed data from large population studies and found that people with higher Klotho levels had significantly lower rates of:

• Heart disease
• Stroke
• Type 2 diabetes
• Chronic kidney disease
• Metabolic syndrome

Klotho protects blood vessels through several mechanisms. It suppresses vascular calcification — the hardening of arteries that drives heart disease. It reduces oxidative stress by increasing antioxidant enzyme expression (SOD, catalase). And it blocks the Wnt signaling pathway, which when overactive promotes fibrosis (scarring) in the heart and kidneys.

In kidney health specifically, Klotho is critical. The kidneys are the primary source of circulating Klotho. Chronic kidney disease (CKD) causes a dramatic drop in Klotho levels — which in turn accelerates cardiovascular damage, creating a vicious cycle. Research published in Frontiers in Endocrinology (2025) confirmed that Klotho deficiency worsens diabetic kidney disease progression.

No FDA-approved Klotho therapy exists as of 2026. However, research has identified several factors that influence Klotho expression:

Exercise: Regular aerobic exercise increases circulating s-Klotho levels. A meta-analysis found that moderate-intensity exercise (3-5 sessions per week) raised Klotho by 15-20% over 12-24 weeks. High-intensity interval training (HIIT) also showed positive effects.

Vitamin D: Active vitamin D (calcitriol) upregulates Klotho gene expression. Research shows that vitamin D-deficient individuals have significantly lower Klotho levels, and supplementation partially restores them.

Caloric restriction: Animal models consistently show that caloric restriction (20-30% reduction) increases Klotho expression. The mechanism involves reduced insulin/IGF-1 signaling and lower oxidative stress — both of which support Klotho production.

Emerging approaches: Several experimental strategies are under investigation:

• Recombinant Klotho protein: Direct injection of Klotho protein improved cognition in aged mice (UC San Francisco studies). Human trials have not yet begun
• Gene therapy: GARM Clinic (Honduras) offers non-permanent Klotho gene therapy as an experimental procedure. This aims to temporarily increase Klotho production at the cellular level
• Small-molecule activators: Drug discovery programs are screening compounds that upregulate Klotho gene expression. No candidates have entered clinical trials yet

Chronic low-grade inflammation — often called "inflammaging" — is a hallmark of biological aging. Klotho acts as an anti-inflammatory brake on this process.

Klotho suppresses NF-kB signaling, the master switch for inflammatory gene expression. By blocking NF-kB, Klotho reduces production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. This is the same pathway targeted by anti-inflammatory peptides like KPV and BPC-157.

Research also shows that Klotho reduces oxidative stress — a key driver of inflammation. Klotho increases the expression of manganese superoxide dismutase (MnSOD) and other antioxidant enzymes. Lower oxidative stress means less cellular damage and fewer inflammatory signals.

In preclinical models, Klotho administration reduced inflammatory markers in:

• Kidney disease models (reduced renal fibrosis and inflammation)
• Cardiac models (less post-infarction inflammatory damage)
• Brain models (reduced neuroinflammation and microglial activation)

For more on anti-inflammatory peptide mechanisms, see the inflammation peptide guide.

Klotho research is promising but still early-stage. Several challenges remain before Klotho-based therapies reach clinical use.

No human clinical trials yet: As of 2026, no exogenous Klotho product has entered formal human clinical trials. The preclinical data is strong, but human dosing, safety, and efficacy remain unestablished.

Delivery challenges: Klotho is a large protein (approximately 130 kDa for the full-length form). This makes oral delivery impossible and even injectable delivery complex. Fragments or peptide mimetics may be needed for practical therapeutic use.

Measurement standardization: Assays for circulating s-Klotho levels are not yet standardized across laboratories. This makes it difficult to compare results across studies and establish clinical reference ranges.

What to watch for:

• UC San Francisco's continued work on recombinant Klotho for cognitive aging
• Lionheart Health's Klotho-Up study tracking lifestyle interventions and Klotho levels
• Small-molecule Klotho activator drug discovery programs
• Gene therapy approaches offering temporary Klotho expression boosts

Klotho represents a shift in anti-aging research — from treating age-related diseases individually to targeting a single upstream factor that influences multiple aging pathways simultaneously. Research listings link to third-party sellers for peptide research. PurePep does not sell or certify products.